Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Acquires Morphotek s Cell Line Evolution Business; Morphotek to Use Cash to Finance Trials

NEW YORK, Jan. 6 (GenomeWeb News) - Invitrogen has acquired Morphotek's cell line evolution service business for an undisclosed amount, the company said yesterday.

 

Under the transaction, Morphotek retained rights to its Human Morphodoma antibody technology platform.

 

According to Nicholas Nicolaides, Morphotek's president and CEO, funding from this transaction will support current clinical trials as well as future therapeutic candidates.

 

Invitrogen is now the exclusive provider of the cell line evolution technology, Revolution, to the biotechnology and agricultural industries, Morphotek said.

 

Financial terms were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.